TECH vs. NBIX, QGEN, RGEN, PCVX, EXEL, RVMD, IBRX, HALO, ARGX, and CRSP
Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), argenx (ARGX), and CRISPR Therapeutics (CRSP). These companies are all part of the "biological products, except diagnostic" industry.
Neurocrine Biosciences (NASDAQ:NBIX) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment.
In the previous week, Neurocrine Biosciences had 12 more articles in the media than Bio-Techne. MarketBeat recorded 20 mentions for Neurocrine Biosciences and 8 mentions for Bio-Techne. Neurocrine Biosciences' average media sentiment score of 1.34 beat Bio-Techne's score of 0.80 indicating that Bio-Techne is being referred to more favorably in the news media.
Neurocrine Biosciences has a net margin of 18.65% compared to Neurocrine Biosciences' net margin of 17.59%. Bio-Techne's return on equity of 17.45% beat Neurocrine Biosciences' return on equity.
Neurocrine Biosciences received 595 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.58% of users gave Neurocrine Biosciences an outperform vote while only 62.48% of users gave Bio-Techne an outperform vote.
Neurocrine Biosciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.
92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 4.5% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Bio-Techne has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Neurocrine Biosciences presently has a consensus target price of $148.96, indicating a potential upside of 4.69%. Bio-Techne has a consensus target price of $80.50, indicating a potential downside of 3.94%. Given Bio-Techne's higher possible upside, equities analysts plainly believe Neurocrine Biosciences is more favorable than Bio-Techne.
Summary
Neurocrine Biosciences beats Bio-Techne on 11 of the 19 factors compared between the two stocks.
Get Bio-Techne News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Techne Competitors List
Related Companies and Tools
